Apps

Lindsay Clancy trial ends in mistrial after jury deadlocks 11-1 — 1dA Plymouth Superior Court jury deadlocked in Lindsay Clancy’s murder case, prompting a mistrial after seven weeks of deliberations. The defense questioned a lone holdout juror while prosecutors emphasized the victims in the deaths of her three children.

Clancy trial deadlocked as defense seeks removal of holdout juror — 2d

Rachel Meyers Judges usually only remove jurors for misconduct, not for holding an opinion others don't share. Curious what grounds they're actually citing here.

Mistrial declared in Lindsay Clancy murder case, retrial timing unclear — 1dThe Lindsay Clancy murder trial was declared a mistrial, leaving the question of whether she will be retried and when still unresolved, as coverage from NBC and NBC Boston highlights ongoing legal proceedings and potential next steps. Republican Rep. Brandon Gill criticized Clancy on a talk show, saying he has no sympathy for her, reflecting partisan reaction to the case.

Video — YouTubeMISTRIAL: MA v. Lindsay Clancy - Day 28 | Accused Killer Mom TrialCOURT TV · 3.4M views · Sep 4, 2026

8:21:43

Jury deadlocks in high-profile Lindsay Clancy trial — 5dThe Plymouth, Massachusetts jury in Lindsay Clancy’s murder trial remains deadlocked after multiple days of deliberations, with prosecutors contending the killings were premeditated and the defense attributing the actions to postpartum psychosis. If no verdict is reached, a mistrial could be declared and the case might be retried or resolved through other means, as jurors are guided to continue considering opposing views under the Tuey-Rodriguez instruction.

Novartis Phase 3 Pelacarsen Trial Misses Cardiovascular Endpoint — 21hNovartis reported that the Phase III Lp(a)HORIZON trial did not meet its primary endpoint, showing that lowering Lp(a) with pelacarsen reduced levels but did not significantly reduce cardiovascular events in approximately 8,000 patients on guideline-directed therapy; the company said full data will be presented at a future medical congress. Meanwhile, Royalty Pharma outlined its financial stance on the pelacarsen investment, noting the trial’s failure won’t derail its recovery of invested funds and that royalties on Spinraza remain a key part of its portfolio as it pursues its 2030 receipts target, with Ionis royalties potentially reverting after a defined cap. The developments reflect a broader scientific and market reevaluation of Lp(a)-targeted therapies and their commercial prospects.

Jared Kim Wonder how many other Lp(a) drugs in the pipeline just got a lot riskier to fund after this readout.

Utah judge weighs whether Tyler Robinson stands trial for Kirk killing — 5dAcross multiple Utah hearings, prosecutors seek to bound Tyler Robinson’s case for trial on aggravated murder with the death-penalty option still on the table, and judges are expected to keep that possibility as the proceedings move forward. Legal experts note the preliminary phases hinge on probable-cause findings, surveillance footage, and witness testimony, with rulings anticipated on whether the case advances toward trial and potential pleas.

Broncos LB Cooper pleads not guilty; trial set — 5dBroncos linebacker Jonathon Cooper pleaded not guilty to multiple domestic-violence charges in Douglas County, with a jury trial set for November 10 and a pretrial hearing on October 30. He remains on the NFL’s Commissioner’s Exempt List and is on paid leave as the league reviews potential discipline while Denver monitors the legal developments and supports him.

Telix completes BiPASS trial enrollment, aligns with FDA on NDA path — 3dTelix has completed enrollment of 350 patients in its Phase 3 BiPASS trial evaluating Ga-68 PSMA-PET plus MRI for pre-biopsy prostate cancer detection, with the aim of improving diagnostic accuracy and reducing unnecessary biopsies. The company also aligned with the FDA on a New Drug Application pathway that could support reimbursement and broaden patient access if approved, a development that sparked investor interest.

Elena Vasquez patients enrolled is solid for a Phase 3, curious how the imaging combo compares to standard biopsy in real practice.

NeuroThera advances enrollment in SCI-210 autism trial toward 60-participant goal — 5dNeuroThera Labs’ SCI-210, a CBD-CannAmide formulation for autism, is advancing in a double-blind trial at Soroka Medical Center in Israel, with enrollment moving toward 60 participants and early momentum reported (six in Article 1, 26 by mid-trial updates in Articles 2 and 3) and endpoints including the ABC-C and CGI-I assessments. The program, conducted under NeuroThera as a SciSparc subsidiary, aims to determine whether SCI-210 offers advantages over CBD alone, with plans to commercialize initially in Israel if successful.

Chris Dalton Commercializing in Israel first makes sense before trying to scale anywhere else, smart move if the data holds up.

Yorgen Fenech acquitted in Caruana Galizia murder — 5dThe Maltese businessman Yorgen Fenech has been acquitted of masterminding and conspiring in the 2017 car-bomb murder of Daphne Caruana Galizia, after a lengthy trial and years in pre-trial detention. Five men were already convicted as the hit’s executors, while the case raises ongoing questions about Malta’s political ties and journalist safety, with defense arguing that Keith Schembri was the true mastermind.

Video — YouTubeVERDICT WATCH: MA v. Lindsay Clancy - Day 27 | Accused Killer Mom TrialCOURT TV · 2.8M views · Sep 3, 2026

9:18:21

UK regulator to phase out Tavneos after finding trial data unreliable — 4dBritain's MHRA suspended the use and sale of Tavneos (Avacopan Vifor) for new patients after deeming the pivotal trial data unreliable, with a six-month window for continuing treatment and a planned UK market revocation by March 1, 2027. Amgen and CSL Vifor dispute the decision, arguing that the broader evidence supports the drug's benefits, while regulators in the EU and US have also flagged concerns about data reliability and potential withdrawals.

Rachel Meyers If EU and US regulators are all flagging the same data problems, that's a pretty strong signal something's genuinely wrong with the trial, not just one agency being cautious.

BioNTech halts Phase 2 cancer vaccine trialHealth — Aug 28, 2026BioNTech and Genentech/Roche have terminated the Phase 2 trial of autogene cevumeran for ctDNA-positive, surgically resected high-risk colorectal cancer after an independent DSMB cited a numerical survival imbalance, with further continuation deemed unlikely to change outcomes. The company will analyze the data to refine patient selection, and a separate Phase 2 trial in pancreatic cancer remains ongoing.

FDA approves Ionis' Zanvastro as first treatment for rare Alexander disease — 2dThe FDA approved Zanvastro (zilganersen) from Ionis as the first disease-modifying therapy for Alexander disease, a rare GFAP-related brain disorder, for adults and children. The intrathecal antisense oligonucleotide lowers abnormal GFAP protein and trials showed stabilization or improvement in motor function with a favorable safety profile, though administration requires specialized settings.

Elena Vasquez Intrathecal delivery is going to be a barrier for a lot of families depending on where they live. Access to specialized centers matters just as much as the approval itself.

Clancy Trial Deliberations Enter Sixth Day — Aug 28, 2026Jurors in Lindsay Clancy’s murder trial have not reached a verdict after a second day of deliberations and are set to resume Monday, weighing first- or second-degree murder, manslaughter, or insanity-based verdicts. The case centers on whether Clancy was criminally responsible at the time of the killings or suffering postpartum psychosis, with prosecutors arguing intent and control and the defense emphasizing mental illness.